Retatrutide

Investigational triple agonist (GLP-1 / GIP / glucagon) with the largest weight-loss effect of any compound yet reported in its class.

Overview

Retatrutide is Eli Lilly's investigational "triple agonist" - a single molecule that activates the GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon agonism is the distinctive feature, and appears to drive additional energy expenditure alongside the appetite-suppression and metabolic effects of the GIP/GLP-1 components. In Phase 2 data, retatrutide produced ~24% mean body weight reduction at 48 weeks at the highest dose - the largest effect reported to date for any pharmacologic weight-loss compound.

Retatrutide is currently in Phase 3 trials and is not FDA-approved. Most current usage in the community is from research chemical suppliers or gray-market sources, which raises quality and dosing accuracy concerns relative to FDA-approved semaglutide and tirzepatide. Users considering retatrutide should carefully evaluate source quality and work with a physician who can monitor both weight and the broader metabolic picture.

Beyond weight, early retatrutide data has shown favorable movement on metabolic markers - HbA1c, ApoB, triglycerides, hepatic steatosis markers. One watch item: retatrutide has produced modest heart-rate elevation (~4–6 bpm) in trials, which should be tracked in anyone with existing cardiovascular considerations.

Mechanism of Action

Retatrutide is a synthetic single-chain peptide that activates three receptors: GIP (insulinotropic, adipose tissue modulation), GLP-1 (insulin secretion, glucagon suppression, appetite reduction, gastric emptying), and glucagon (hepatic glucose output, energy expenditure). The glucagon agonism is what drives additional caloric burn beyond appetite reduction alone, effectively producing a "metabolic acceleration" layered on top of the appetite-suppression effects.

Community Usage Patterns

Research dosing in Phase 2 escalated 2 mg → 12 mg over 12 weeks. Most community protocols use a similar slow titration starting at 1–2 mg. No pharmacy-compounded version exists in the US; all current access is via research chemical channels. Tracking: weight, HbA1c, lipid panel (with ApoB), fasting glucose, heart rate, LFTs. Because of the glucagon component, hepatic markers (ALT, AST) deserve baseline and ongoing monitoring.

Education only - not medical advice. Any protocol change should involve your licensed provider.

Deep Dive

The third receptor: why glucagon agonism is the defining design choice

Semaglutide is a single GLP-1 agonist. Tirzepatide adds GIP to make a dual agonist. Retatrutide's distinguishing move is the third arm, glucagon receptor agonism, and understanding why that arm is hard to engineer explains most of what makes the molecule interesting.

Glucagon in isolation raises blood sugar. It signals the liver to release stored glucose, the opposite of what a diabetes or weight compound is trying to do, and for years that made glucagon agonism look like a dead end. The design insight behind retatrutide is that glucagon also drives energy expenditure, lipolysis, and hepatic fat oxidation, and that its glucose-raising tendency can be counterbalanced by pairing it with the insulin-promoting, appetite-suppressing GIP and GLP-1 signals inside a single tuned molecule. The relative potency at each receptor is deliberately weighted so the net metabolic effect comes out favorable rather than hyperglycemic. That same balance is the most credible explanation for the liver-fat findings discussed below: glucagon pushes the liver to burn its own fat stores, an effect the pure GLP-1 drugs do not produce to the same degree.

What the human evidence shows, and where it now stands

Retatrutide's evidence base moved beyond mid-stage trials during 2026, so an honest summary has to separate the detailed Phase 2 readouts from the early Phase 3 data now emerging.

The three landmark Phase 2 readouts, each a randomized controlled trial, remain the most granular public dataset:

- Obesity (Jastreboff, New England Journal of Medicine, 2023, n=338, 48 weeks): least-squares mean body-weight change of -24.2% at 12 mg and -22.8% at 8 mg, versus -2.1% for placebo. At 48 weeks, 83% of the 12 mg group had lost at least 15% of body weight, and the weight curve had not clearly plateaued by week 48. - Type 2 diabetes (Rosenstock, The Lancet, 2023, n=281, placebo- and dulaglutide-controlled): HbA1c fell by roughly 2.0% at the 12 mg dose, substantially more than placebo, with body weight down about 17% at 36 weeks. - Liver fat (Sanyal, Nature Medicine, 2024, phase 2a MASLD trial, n=98): among participants who started with at least 10% liver fat, mean liver fat fell about 81 to 82% at the 8 and 12 mg doses at 24 weeks, and normal liver fat (under 5%) was reached by 79 to 86% of them, versus essentially none on placebo.

During 2026 the first Phase 3 readouts arrived and broadly reproduced these effect sizes. TRANSCEND-T2D-1, a Phase 3 type 2 diabetes trial (n=537, 40 weeks), was published in The Lancet in June 2026 and reported an HbA1c reduction of about 1.9% and roughly 17% weight loss at the 12 mg dose. TRIUMPH-1, the pivotal Phase 3 obesity trial (n=2,339, 80 weeks), was presented at the American Diabetes Association 2026 Scientific Sessions with a reported mean weight reduction of about 28% at the 12 mg dose. As of this writing TRIUMPH-1 had been announced and presented but not yet published in a peer-reviewed journal, so it should be read as conference-stage data rather than a fully vetted publication.

What is still open matters as much as what has reported. There is no dedicated cardiovascular outcomes trial readout, no multi-year safety record, and no data on how durable the effect is after stopping. Those remain the honest limits of the evidence, and they are why retatrutide is still described as investigational rather than proven.

Biomarkers commonly tracked on a retatrutide protocol

Because the glucagon arm makes retatrutide behave differently from a pure GLP-1, the markers reported in the literature tend to be broader than the weight-plus-HbA1c panel common with semaglutide. Commonly reported, with the reasoning behind each:

- Fasting glucose and HbA1c: the counterintuitive one. Glucagon agonism can nudge hepatic glucose output upward, so glycemia is the read-through for whether the GIP and GLP-1 arms are adequately offsetting the glucagon arm. In the trials the net effect was clearly favorable, but individual response varies. - ALT, AST, and where available liver-fat imaging: the glucagon-driven fat oxidation is the mechanism behind the dramatic liver-fat data, so hepatic markers double as both a safety check and a signal of the intended effect. - ApoB with a full lipid panel including triglycerides: reported as the cardiometabolic read-through, since ApoB reflects atherogenic particle number more directly than LDL-C alone. - Heart rate and blood pressure: covered below. - Kidney markers (creatinine, eGFR): rapid weight loss combined with fluid losses from nausea, vomiting, or diarrhea can affect hydration and renal readings. - Body composition, for example by DEXA: any agent producing 20%-plus weight loss raises the question of how much of the loss is lean mass, which no single blood marker captures.

None of this is medical advice or a monitoring prescription. It is a description of markers researchers and clinicians have reported watching, and any tracking plan should be built with a licensed clinician.

The heart-rate signal and cardiovascular watch-items

Every drug in this class raises heart rate modestly, and retatrutide is no exception. In the obesity trial the increase was dose-dependent, peaked around week 24, and then declined through week 48, a more reassuring pattern than a sustained climb. Even so, resting heart rate is one of the more concrete things a clinician may choose to follow over time, particularly for anyone with existing cardiovascular considerations, and it pairs naturally with blood pressure, which the GLP-1 class tends to lower. Because no cardiovascular outcomes trial has reported, the net long-term cardiovascular effect is still unknown, which is exactly why this class of marker draws attention rather than assumption.

Regulatory status and the compounding reality

The single most important regulatory fact is one the approved GLP-1 drugs do not share. Retatrutide has never been FDA-approved, which means it cannot be legally compounded by a pharmacy. Compounding under 503A or 503B rules generally requires an approved reference product or a listed bulk substance, and retatrutide is neither. When semaglutide and tirzepatide were in shortage, compounded versions existed in a defined legal gray zone tied to their approved status. No equivalent legitimate pharmacy channel exists for retatrutide.

In practice that means essentially all non-trial access runs through research-chemical suppliers, where identity, purity, dose accuracy, and sterility are not verified to pharmaceutical standards. That is a materially different risk profile from a prescription GLP-1, and it is the honest starting context for any discussion about tracking a protocol. This status may change as the Phase 3 program matures: an FDA filing is anticipated in late 2026 or early 2027 once the TRIUMPH obesity trials read out in full, with any approval decision further out still. Until an approval actually lands, retatrutide remains strictly investigational, and none of the above is a recommendation to obtain or use it. Any decision about it belongs with a licensed clinician.

Biomarkers to Track

When running Retatrutide, these are the biomarkers most commonly tracked to assess response and safety:

Blood Work Checklist

Before starting Retatrutide, baseline the right panel. The Peptide Blood Work Checklist covers the full baseline panel, what to add for Retatrutide's class, and when to retest.

Reconstitution Calculator

Free calculator for Retatrutide reconstitution math - vial size, BAC water volume, and exact syringe units.

Side Effects & Monitoring

What Retatrutide side effects are commonly reported, when they appear, the red flags worth a provider call, and the biomarkers that catch issues early.

Results & What to Track

What Retatrutide results actually look like in the data - the markers to measure, when they tend to move, and how to tell a real result from placebo.

Related Reading

• Retatrutide Protocol Guide →
• Glp1 Titration Schedule Guide →
• Apob Cardiovascular Risk Peptides →

Related Peptides

Retatrutide Head-to-Head Comparisons

Conditions Retatrutide is Commonly Researched For

Frequently Asked Questions

Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.